All In Biotech

Drug Trial Radar · NCT06613685

Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

An Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Treatment-Naive People With HIV-1

Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

73

Actual

Start

Oct 21, 2024

Primary completion

Mar 16, 2026

Study completion Mar 16, 2026

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Sep 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the experimental drugs lepetegravir (formerly GS-1720) (an oral, long-acting integrase strand transfer inhibitor (INSTI)) and lenacapavir pacfosacil (formerly GS-4182) (a prodrug of Lenacapavir (LEN)); to compare the combination of lepetegravir and lenacapavir pacfosacil with the current standard-of-care treatment bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (Biktarvy), to see if the combination of lepetegravir and lenacapavir pacfosacil is safe and if it works for treating human immunodeficiency virus type 1 (HIV-1) infection in treatment-naive people with HIV-1 (PWH). This study has two phases: Phase 2 and Phase 3. The primary objectives of this study are: Phase 2: To evaluate the efficacy of oral weekly lepetegravir coadministered with lenacapavir pacfosacil versus continuing Biktarvy (BVY) in treatment-naive PWH at Week 24. Phase 3: To evaluate the efficacy of oral weekly lepetegravir/lenacapavir pacfosacil fixed-dose combination (FDC) tablet regimen versus continuing BVY in treatment-naive PWH at Week 48.

Conditions

  • HIV-1-infection

Interventions

  • lepetegravirDrug

    Tablets administered orally without regard to food

  • lenacapavir pacfosacilDrug

    Tablets administered orally without regard to food

  • Bictegravir/emtricitabine/tenofovir alafenamideDrug

    Tablets administered orally without regard to food

  • lepetegravir/lenacapavir pacfosacil FDCDrug

    Tablets administered orally without regard to food

  • Placebo to Match BVYDrug

    Tablets administered orally without regard to food

  • Placebo to Match GS1720/GS-4182 FDCDrug

    Tablets administered orally without regard to food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the United States (US) Food and Drug Administration (FDA)-defined Snapshot AlgorithmTime frame: Week 24
  2. Phase 3: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 48

Locations

58 sites in 9 countries. Site status is shown where the registry gives one.

  • UAB 1917 Research Clinic

    Birmingham, Alabama

  • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Mills Clinical Research

    West Hollywood, California

  • Georgetown University Medical School

    Washington D.C., District of Columbia

  • Midland Florida Clinical Research Center, LLC

    DeLand, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • Floridian Clinical Research, LLC

    Miami Lakes, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Triple O Research Institute, P.A.

    West Palm Beach, Florida

  • Emory University Hospital Midtown Infectious Disease Clinic

    Atlanta, Georgia

  • Mercer University, Department of Internal Medicine

    Macon, Georgia

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Saint Michael's Medical Center

    Newark, New Jersey

  • NYU Langone Health Vaccine Center

    New York, New York

  • Medical University of South Carolina (MUSC) Research Nexus

    Charleston, South Carolina

  • St Hope Foundation, Inc.

    Bellaire, Texas

  • Prism Health North Texas, Aids Arms

    Dallas, Texas

  • North Texas Infectious Diseases Consultants, PA

    Dallas, Texas

  • Texas Centers for Infectious Disease Associates

    Fort Worth, Texas

  • UT Health San Antonio

    San Antonio, Texas

  • MultiCare Rockwood Main Clinic

    Spokane, Washington

  • Clinique Médicale L'Actuel

    Montreal, Canada

  • Chronic Viral Illness Service / McGill University Health Centre

    Montreal, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Canada

  • Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I, Immunologische Studienambulanz

    Bonn, Germany

  • Universitätsmedizin Essen, Universitätsklinikum Essen, Klinik für Dermatologie, Venerologie und Allergologie, HPSTD-Ambulanz

    Essen, Germany

  • ICH Study Center GmbH & Co. KG

    Hamburg, Germany

  • Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie, Gebäude K14

    Hanover, Germany

  • Klinikum rechts der Isar, Technische Universität München, Klinik und Poliklinik für Innere Medizin II

    München, Germany

  • Wojewódzki Szpital Obserwacyjno-Zakaźny im. Tadeusza Browicza

    Bydoszcz, Poland

  • Punkt Zdrowia

    Gdansk, Poland

  • Samodzielny Publiczny Wojewódzki Szpital Zespolony w Szczecinie

    Szczecin, Poland

  • Unidade Local de Saude de Amadora Sinatra EPE, Hospital Prof. Doutor Fernando Fonseca

    Amadora, Portugal

  • Unidade Local de Saúde de Lisboa Ocidental E.P.E. - Hospital Egas Moniz

    Lisbon, Portugal

  • Unidade Local de Saúde de Santo Maria E.P.E. - Hospital Santa Maria

    Lisbon, Portugal

  • Unidade Local de Saúde de Santo António, E.P.E.

    Porto, Portugal

  • Unidade Local de Saúde de São João E.P.E.

    Porto, Portugal

  • HOPE Clinical Research

    San Juan, PR, Puerto Rico

  • Proyecto ACTU

    San Juan, PR, Puerto Rico

  • Institutul National De Boli Infectioase Prof. Dr. Matei Bals

    Bucharest, Romania

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.